Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Liquid Biopsy Market – Insights

Liquid biopsy is an advanced cancer diagnostic test that uses bio-fluids such as blood, cerebrospinal fluid (CSF), plasma, and urine for detecting cancer. This non-invasive diagnostic test uses circulating nucleic acids, circulating tumor cells (CTC), and exosomes as biomarkers for diagnosis of cancer.

The global liquid biopsy market is estimated to account for US$ 3,535.1 Mn in terms of value by the end of 2027.

Global Liquid Biopsy Market: Drivers

Increasing prevalence of cancer is a major factor propelling growth of the global liquid biopsy market over the forecast period. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018.

Moreover, increasing funding for R&D in cancer is also expected to aid in growth of the market. For instance, according to the National Cancer Research Institute (NCRI), cancer research funding by NCRI partners reached around US$ 750 million in 2018/19.

North America region held dominant position in the global liquid biopsy market in 2019, accounting for 50.7% share in terms of value, followed by Europe.

Figure 1. Global Liquid Biopsy Market Value (US$ Mn), by Region, 2019

Liquid Biopsy  | Coherent Market Insights

Global Liquid Biopsy Market: Restraints

Levels of circulating free DNA (cfDNA) in serum and plasma vary. Such changes in cfDNA levels among patients may lead to inaccurate or unreliable test results in liquid biopsy, thereby hindering growth of the global liquid biopsy market.

Moreover, high cost of liquid biopsy is also expected to hinder growth of the market. Various expenses associated with liquid biopsy include cost of equipment & reagents and labor & professional costs.

Global Liquid Biopsy Market: Opportunities

Microfluidics is characterized by the precise manipulation of fluid within sub-millimeter channels. Many researches are ongoing for the development of lab-on-a-chip devices for biochemical analyses such as cell separation, DNA and protein analyses, and PCR amplification.

Moreover, adoption of cfDNA to monitor tumor alterations and tumor progression is expected to offer lucrative growth opportunities for players in the market.

Liquid Biopsy  | Coherent Market Insights

ctNA (Circulating Tumor Nucliec Acids) segment in the global liquid biopsy market was valued at US$ 250.0 Mn in 2019 and is expected to reach US$ 1,723.6 Mn by 2027 at a CAGR of 27.3% during the forecast period.

Market Trends/Key Takeaways

The use of breast milk in diagnosis of breast cancer is being tested. For instance, in February 2020, Dr. Katrina Mitchell, MD, a fellowship-trained breast surgeon of IBCLC, FACS, partnered with University of Massachusetts-Amherst cancer researchers to assess use of breast milk from nursing women for determining pathogenic BRCA1 or BRCA2 genetic mutation.

Players in the market are focused on partnering with various institutes for R&D in liquid biopsy. For instance, in February 2020, Foundation Medicine, Inc. and Chugai Pharmaceutical, Ltd. collaborated with National Cancer Center (NCC) for the use of FoundationOneLiquid, Foundation Medicine’s laboratory-developed liquid biopsy test, in the third stage of SCRUM-Japan, a cancer genomic screening consortium in Japan.

Global Liquid Biopsy Market: Competitive Landscape

Major players operating in the global liquid biopsy market include, Biocept, Inc., Qiagen N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation.

Global Liquid Biopsy Market: Key Developments

Major players in the market are focused on adopting partnership strategies to expand their product portfolio. For instance, in January 2020, Saga Diagnostics signed agreements with Laboratoires Servier to perform liquid biopsy testing on cancer patients enrolled in clinical studies.

Major players in the market are also focused on presenting their products at major symposiums. For instance, in January 2020, GRAIL, Inc. presented new data from its trial, CCGA, for liquid biopsy at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, which failed to show marked improvement in sensitivity compared with data presented at the symposium in 2019.

Liquid biopsy is an advanced non-invasive cancer diagnostic technique that uses bio-fluids such as blood, cerebrospinal fluid (CSF), plasma, and urine for detecting cancer. Liquid biopsy uses circulating nucleic acids, circulating tumor cells (CTC), and exosomes as biomarkers for diagnosis of cancer. Increasing demand for non-invasive diagnostic procedures is expected to boost growth of the global liquid biopsy market over the forecast period. Furthermore, increasing prevalence of cancer is a major factor propelling growth of the global liquid biopsy market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the global Liquid Biopsy and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global Liquid Biopsy based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans
  • Key companies covered as a part of this study include Biocept, Inc., Qiagen N.V., Trovagene, Inc., Janssen Global Services, LLC, MDxHealth SA, Natera, Inc., F. Hoffmann-La Roche Ltd., Silicon Biosystems, Pathway Genomics Corporation, and Sysmex Corporation.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global Liquid Biopsy report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Liquid Biopsy Market, By Biomarker Type:
    • CTC (Circulating Tumor Cells)
    • ctNA (Circulating Tumor Nucliec Acids)
    • Exosomes
  • Liquid Biopsy Market, By Sample Type:
    • Blood
    • Urine
    • Others
  • Liquid Biopsy Market, By Disease Indication:
    • Lung Cancer
    • Gastrointestinal Cancer
    • Prostate Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Leukemia
    • Others
  • Liquid Biopsy Market, By End User:
    • Hospitals
    • Cancer Institutes
    • Academic Institutes
    • Diagnostic Centers
  • Liquid Biopsy Market, By Region:
    • North America
      • By Biomarker Type:
        • CTC (Circulating Tumor Cells)
        • ctNA (Circulating Tumor Nucliec Acids)
        • Exosomes
      • By Sample Type
        • Blood
        • Urine
        • Others
      • By Disease Indication
        • Lung Cancer
        • Gastrointestinal Cancer
        • Prostate Cancer
        • Breast Cancer
        • Colorectal Cancer
        • Leukemia
        • Others
      • By End User
        • Hospitals
        • Cancer Institutes
        • Academic Institutes
        • Diagnostic Centers
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Biomarker Type:
        • CTC (Circulating Tumor Cells)
        • ctNA (Circulating Tumor Nucliec Acids)
        • Exosomes
      • By Sample Type
        • Blood
        • Urine
        • Others
      • By Disease Indication
        • Lung Cancer
        • Gastrointestinal Cancer
        • Prostate Cancer
        • Breast Cancer
        • Colorectal Cancer
        • Leukemia
        • Others
      • By End User
        • Hospitals
        • Cancer Institutes
        • Academic Institutes
        • Diagnostic Centers
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Biomarker Type:
        • CTC (Circulating Tumor Cells)
        • ctNA (Circulating Tumor Nucliec Acids)
        • Exosomes
      • By Sample Type
        • Blood
        • Urine
        • Others
      • By Disease Indication
        • Lung Cancer
        • Gastrointestinal Cancer
        • Prostate Cancer
        • Breast Cancer
        • Colorectal Cancer
        • Leukemia
        • Others
      • By End User
        • Hospitals
        • Cancer Institutes
        • Academic Institutes
        • Diagnostic Centers
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Biomarker Type:
        • CTC (Circulating Tumor Cells)
        • ctNA (Circulating Tumor Nucliec Acids)
        • Exosomes
      • By Sample Type
        • Blood
        • Urine
        • Others
      • By Disease Indication
        • Lung Cancer
        • Gastrointestinal Cancer
        • Prostate Cancer
        • Breast Cancer
        • Colorectal Cancer
        • Leukemia
        • Others
      • By End User
        • Hospitals
        • Cancer Institutes
        • Academic Institutes
        • Diagnostic Centers
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Biomarker Type:
        • CTC (Circulating Tumor Cells)
        • ctNA (Circulating Tumor Nucliec Acids)
        • Exosomes
      • By Sample Type
        • Blood
        • Urine
        • Others
      • By Disease Indication
        • Lung Cancer
        • Gastrointestinal Cancer
        • Prostate Cancer
        • Breast Cancer
        • Colorectal Cancer
        • Leukemia
        • Others
      • By End User
        • Hospitals
        • Cancer Institutes
        • Academic Institutes
        • Diagnostic Centers
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Biomarker Type:
        • CTC (Circulating Tumor Cells)
        • ctNA (Circulating Tumor Nucliec Acids)
        • Exosomes
      • By Sample Type
        • Blood
        • Urine
        • Others
      • By Disease Indication
        • Lung Cancer
        • Gastrointestinal Cancer
        • Prostate Cancer
        • Breast Cancer
        • Colorectal Cancer
        • Leukemia
        • Others
      • By End User
        • Hospitals
        • Cancer Institutes
        • Academic Institutes
        • Diagnostic Centers
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Biocept, Inc. *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • Qiagen N.V
    • Trovagene, Inc.
    • Janssen Global Services, LLC
    • MDxHealth SA
    • Natera, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Silicon Biosystems
    • Pathway Genomics Corporation
    • Sysmex Corporation

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Biomarker Type
      • Market Snippet, By Sample Type
      • Market Snippet, By Disease Indication
      • Market Snippet, By End User
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Technological Advancement
    • Regulatory Scenario
  4. Global Liquid Biopsy Market, By Biomarker Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • CTC (Circulating Tumor Cells)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2027, (US$ Mn)
    • ctNA (Circulating Tumor Nucliec Acids)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2027, (US$ Mn)
    • Exosomes
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2027, (US$ Mn)
  5. Global Liquid Biopsy Market, By Sample Type, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Blood
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2027, (US$ Mn)
    • Urine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2027, (US$ Mn)
  6. Global Liquid Biopsy Market, By Disease Indication 2019– 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Lung Cancer
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Gastrointestinal Cancer
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Prostate Cancer
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Breast Cancer
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Colorectal Cancer
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Leukemia
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Liquid Biopsy Market, By End User 2019– 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Cancer Institutes
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Academic Institutes
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Diagnostic Centers
      • Introduction
      • Market Size, Volume and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  8. Global Liquid Biopsy Market, By Region, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Biomarker Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Sample Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Biomarker Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Sample Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Biomarker Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Sample Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Biomarker Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Sample Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Biomarker Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Sample Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Biomarker Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Sample Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Company Profiles
      • Biocept, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Qiagen N.V
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Trovagene, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Janssen Global Services, LLC
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • MDxHealth SA
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Natera, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • F. Hoffmann-La Roche Ltd
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Silicon Biosystems
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Pathway Genomics Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sysmex Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 24 market data tables and 20 figures on “Liquid Biopsy – Global forecast to 2027.

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner